Sino Biopharm drug shows positive breast cancer trial results
Sino Biopharmaceutical (HKEX: 1177) announced positive results from a Phase III clinical study of Culmerciclib (TQB3616) in combination with Fulvestrant as a first-line treatment for HR-positive and HER2-negative advanced breast cancer. The study met its predefined superiority threshold in an interim analysis, with the combination therapy significantly reducing the risk of disease progression or death. Culmerciclib is a novel CDK2/4/6 inhibitor. The company has already communicated with China's Centre for Drug Evaluation (CDE) and received consent to submit a marketing application for this additional indication. The company also plans to submit the application in the near future. The company's treatment targets the 65-70% of breast cancer patients with HR-positive, HER2-negative breast cancers, which it hopes to provide treatment options for a wider range of female patients.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime